TaRGeT laboratory is based in Nantes Université, at the 4th and 5th floors of “Nantes Biotech/Institut de Recherche en Santé 2 (IRS2)" building.

UMR 1089 (before known as U649) is an internationally recognized expert in the field of gene therapy using viral vectors, in particular in Adeno-Associated Virus-derived vectors (AAV).

The lab has put together a large number of scientific and technological skilled expertise to advance AAV gene therapy products to the clinic among which:

  • vector design and engineering,
  • vector preclinical evaluation in neuromuscular and retinal diseases,
  • vector immunogenicity and
  • vector large scale bioproduction.
IRS2 Nantes Biotech building
It is composed in 5 groups and 3 core facilities working together, closely helped by a quality management support :


Translational vector core dedicated to process and analytics developments in the field of AAV manufacturing.
 


Core for monitoring host immune response in gene therapy studies.

 


Platform dedicated to the evaluation of the biodistribution/shedding and of the expression profiles following in vivo administration of gene therapy products.

The Translational vector core (CPV for “Centre de Production des Vecteurs”) created in 1997
has been labelled by the French government in 2020 as one among the 6 national industrial integrators
of the “Grand Défi National des Biomédicaments”.

The laboratory offers a unique setting in France able to cover the entire translational gene therapy development path :
 

Since 2004, the whole laboratory activities are performed under a quality management system that is approved by Lloyd's Register Quality Assurance LRQA to meet requirements of international Management System Standards ISO 9001:2015.